---
title: "HELP.US (HELP.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HELP.US/news.md"
symbol: "HELP.US"
name: "HELP.US"
parent: "https://longbridge.com/en/quote/HELP.US.md"
datetime: "2026-05-21T18:32:32.224Z"
locales:
  - [en](https://longbridge.com/en/quote/HELP.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HELP.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HELP.US/news.md)
---

# HELP.US (HELP.US) — Related News

### [Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference](https://longbridge.com/en/news/284829118.md)
*2026-04-30T20:17:35.000Z*
> Helus Pharma's Interim CEO, Eric So, will present at the 29th Milken Global Conference on May 4, focusing on mental heal

### [H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP)](https://longbridge.com/en/news/284426300.md)
*2026-04-28T16:35:37.000Z*
> H.C. Wainwright analyst Patrick Trucchio has maintained a Buy rating on Helus Pharma (HELP) with a price target of $95.0

### [Helus Ekes up on Hookup with TARA Mind](https://longbridge.com/en/news/284405613.md)
*2026-04-28T14:17:20.000Z*
> Helus Pharma™ (NASDAQ: HELP) announced a collaboration with TARA Mind to support clinical trial recruitment for its PARA

### [Trump’s Rogan-inspired psychedelics order stokes cautious optimism](https://longbridge.com/en/news/283817386.md)
*2026-04-23T03:05:26.000Z*
> President Trump has signed an executive order to ease research restrictions on psychedelic medicine, inspired by a text 

### [Trump signs executive order to expedite approval of psychedelic therapies](https://longbridge.com/en/news/283712626.md)
*2026-04-22T19:13:02.000Z*
> U.S. President Trump signed an executive order to accelerate research and approval of psychedelic therapies, creating a 

### [Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways](https://longbridge.com/en/news/283408643.md)
*2026-04-20T21:48:08.000Z*
> Helus Pharma supports a new U.S. Executive Order aimed at accelerating research and access to psychedelic treatments for